ALSO NOTED: Par inks commercialization deal on AIDS drug; Innogenetics advances Alzheimer's test; and much more...

> Par Pharmaceuticals is paying $3 million up front for the license to commercialize Immtech's lead oral drug, pafuramidine maleate, in the United States for the treatment of pneumocystis pneumonia in AIDS patients. Another $29 million in milestone payments is scheduled for the successful development of the Phase III product. Release

> Innogenetics NV says it has advanced a blood test that could accelerate development of new therapies for Alzheimer's as well as earlier diagnosis. Report

> Yale is in the process of negotiating for the 17-building, 1.5 million-square-foot research facility Bayer Health Care is leaving in West Haven, CT. The basic plan seems to be to use the space for biotech spin-offs, which has miffed some people in New Haven who want that growth in their town. Report

> Repligen says a court has sanctioned its patent infringement lawsuit against ImClone. Report

> CEL-SCI's cancer drug Multikine has been granted orphan-drug status in patients with squamous cell carcinoma of the head and neck. Release 

> Lonza is boosting its capacity to manufacture active pharma ingredients. Report

> SpectRx has settled its legal dispute with Abbott. Report

> Scientists at Penn and Howard Hughes Medical Institute believe that their investigation of the role fat metabolism plays in the development of Type 2 diabetes has pointed to a new drug target. Report

And Finally... Researchers have found that deleting a gene that plays a key role in embryo development spurs premature aging. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.